Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent
(results from the prospective multicenter German Cypher Stent Registry).
Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent
with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions.
M2 EQUITYBITES-June 16, 2011-Cordis to discontinue NEVO sirolimus-eluting coronary stent
and close manufacturing facilities(C)2011 M2 COMMUNICATIONS http://www.m2.com
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, has announced at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent
have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".
In July, Johnson & Johnson, which markets the sirolimus-eluting coronary stent
(Cypher), and Boston Scientific Corp., which sells the paclitaxel-eluting stent (Taxus), both reported that U.S.
(9) Analysis shows CYPHER Sirolimus-Eluting Coronary Stent
Significantly Reduces Incidence of reblocked Heart Arteries in Women, Including Diabetics and Smokers.
Last year, the company developed the CYPHER[TM] Sirolimus-eluting Coronary Stent
for heart patients, which significantly reduces the likelihood of patients requiring treatment for restenosis, a condition in which a blocked artery that has been cleared becomes clogged again.
Sales and marketing resources of both companies will join forces to focus on promoting the CYPHER Sirolimus-eluting Coronary Stent
in the United States, with an option to pursue a similar arrangement in Japan in the future.
market since 2003 and 2004 are the Cypher sirolimus-eluting coronary stent
manufactured by Cordis Corporation, and the Taxus Express paclitaxel-eluting coronary stent system, respectively.
The first next generation drug-eluting stent, the CYPHER SELECT(TM) Sirolimus-eluting Coronary Stent
, was launched in Europe, Asia Pacific, Latin America and Canada in 2003.
Judge Robinson denied Boston Scientific's request for a preliminary injunction to enjoin Cordis from selling its CYPHER Sirolimus-eluting Coronary Stent
. Boston Scientific alleged that CYPHER infringes a patent relating to polymeric coatings placed on stents.
The RAVEL study was sponsored by Cordis, a division of Johnson and Johnson, which markets the sirolimus-eluting coronary stent